Apart from ibrutinib, people with M-CLL, devoid of TP53 aberrations and match more than enough to tolerate FCR therapy, may still be good candidates with the latter, Along with the reward becoming this treatment may be done in 6 months while ibrutinib needs to be taken indefinitely. This selection could be notably important for non-compliant people